Treace Medical Concepts, Inc. (TMCI) Tops Q2 EPS by 4c

Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $42 million versus the consensus estimate of $40.84 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees FY2023 revenue of $191-197 million, versus the consensus of $194 million.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.

You May Also Be Interested In

• ConAgra Brands (CAG) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY EPS Guidance
• Progressive Corp. (PGR) Reports Q2 EPS of $5.67
• SK Hynix vs. Micron deep dive: who wins the AI memory supercycle?